-
Shanghai’s Argo Biopharma Raises USD 41 Million in Series A+ Financing Round
•
Shanghai-based siRNA drug developer Argo Biopharma has reportedly secured RMB 300 million (USD 41 million) in a Series A+ financing round. The investment round was led by SDIC China Merchants Investment, with additional contributions from Huagai Capital, Yuanxi Haihe Fund, and existing investor Trinity Innovation Fund. The funds will be…
-
ImmuXell Biotech Secures Over RMB 100 Million in Series A Funding for Cell Therapy Development
•
ImmuXell Biotech Co., Ltd, a Shanghai-based cell therapy developer, has reportedly secured over RMB 100 million (USD 13.7 million) in a Series A financing round. The round was led by SDIC Venture Capital, with significant participation from Huangpu Pharmaceutical Fund and Yuanxi Haihe Fund. The funds will be instrumental in…
-
Shanghai Henlius Biotech’s HanSiZhuang Shows Positive Results in Phase III ASTRUM-002 Study
•
Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company in China, has unveiled positive data from the Phase III ASTRUM-002 study. The study assessed the efficacy of its anti-programmed death-1 (PD-1) drug, HanSiZhuang (serplulimab), in combination with chemotherapy for first-line treatment of non-squamous non-small cell lung cancer (nsqNSCLC). The…
-
Luye Pharma Group’s Rivastigmine Patch LY03013 Approved by China’s NMPA for Alzheimer’s Treatment
•
China-based Luye Pharma Group (HKG: 2186) has announced that it has received market approval from the National Medical Products Administration (NMPA) for its rivastigmine twice-weekly transdermal patch (LY03013), a treatment for symptoms of mild and moderate Alzheimer’s disease (AD). Product Development and AdvantagesLY03013, a modified version of rivastigmine, was developed…
-
Bio-Techne Corporation Reports 2% YOY Revenue Growth in Q1 2024 Fiscal Report
•
US-based life sciences service provider Bio-Techne Corporation (NASDAQ: TECH) has released its Q1 report for the fiscal year 2024, which ended on September 30, 2023. The company reported a 2% year-on-year (YOY) increase in revenues, reaching USD 276.9 million. Segment Performance and Revenue BreakdownBio-Techne’s Protein Sciences segment contributed USD 204.7…
-
Novartis’ Cosentyx Gains FDA Approval for Hidradenitis Suppurativa Treatment
•
The US Food and Drug Administration (FDA) has issued regulatory approval for Novartis’ (NYSE: NVS) IL-17A-targeting drug Cosentyx (secukinumab) for the treatment of adult patients with moderate-to-severe hidradenitis suppurativa (HS). This approval positions Cosentyx as a new entrant in the HS biologic therapy market, potentially challenging AbbVie’s (NYSE: ABBV) Humira…
-
AnHeart Therapeutics Signs Exclusive License Deal with Nippon Kayaku for Taletrectinib
•
China-based AnHeart Therapeutics has announced the signing of an exclusive license deal with Japan-based biopharma Nippon Kayaku Co., Ltd. This strategic partnership grants Nippon Kayaku marketing and distribution rights for AnHeart’s leading pipeline candidate, taletrectinib, a next-generation ROS1 inhibitor. Taletrectinib: A Promising Treatment for ROS1-Positive NSCLCTaletrectinib is an oral, potent,…
-
Roche’s Gene Therapy Elevidys Misses Primary Endpoint in DMD Trial
•
Switzerland-headquartered pharmaceutical giant Roche (SWX: ROG) has announced that a Phase III trial for its gene transfer therapy Elevidys (delandistrogene moxeparvovec) did not meet its primary endpoint in Duchenne muscular dystrophy (DMD) ambulatory patients aged 4 to 7 years. The trial aimed to measure the change from baseline in motor…
ADC / XDC AstraZeneca Auto-immune AZ Biotech BMS Bristol-Myers Squibb Cancer CAR-T Cell-therapy Clinical trial approval / initiation Clinical trial results Combination therapy CRO / CMO / CDMO CVD Diabetes Eli Lilly Finance Finanical Reports Gene therapy Hengrui Medicine J&J Johnson & Johnson Market approval filings Merck MSD Multi-specific antibodies NASDAQ: AZN NMPA Novartis NYSE: BMY NYSE: JNJ NYSE: LLY NYSE: MRK NYSE: NVS Obesity Ophthalmology PD-1/L1 Pfizer Potential first-in-class Product approvals Rare / orphan disease drugs SHA: 600276 TKIs (EGFR VEGF BTK etc.) Vaccine
